

Oral Contraceptive Identification Chart



View the full Prescribing Information by clicking on the Teva Generic product name.

Brand	Teva Generic	NDC	Strength(s)	Size
Alesse®	Aviane® (levonorgestrel and ethinyl estradiol tablets, USP)	00555-9045-58	0.1 mg/0.02 mg	6 x 28 Blister Packs
Cyclessa®	Velivet® (desogestrel and ethinyl estradiol tablets, USP - triphasic regimen)	00555-9051-67	0.1 mg/0.025 mg; 0.125 mg/0.025 mg; 0.15 mg/0.025 mg	3 x 28 Blister Packs
Demulen®	Kelnor® 1/35 (ethynodiol diacetate and ethinyl estradiol tablets, USP)	00555-9064-58	1 mg/35 mcg	6 x 28 Blister Packs
	Kelnor® 1/50 (ethynodiol diacetate and ethinyl estradiol tablets USP)	00093-8073-16	1 mg/50 mcg	6 x 28 Blister Packs
Eurostep® Fe*	Tri-Legest® Fe 28 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets ¹)	00555-9032-70	1 mg/20 mcg; 1 mg/30 mcg; 1 mg/35 mcg	5 x 28 Blister Packs
Levlite®	Lessina® (levonorgestrel and ethinyl estradiol tablets, USP)	00555-9014-67	0.1 mg/0.02 mg	3 x 28 Blister Packs
Lo/Ovral®	Cryselle® (norgestrel and ethinyl estradiol tablets, USP)	00555-9049-58	0.3 mg/0.03 mg	6 x 28 Blister Packs
Loestrin® 21	Junel® 1/20 (norethindrone acetate and ethinyl estradiol tablets, USP)	00555-9025-42	1 mg/20 mcg	3 x 21 Blister Packs
	Junel® 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP)	00555-9027-42	1.5 mg/30 mcg	3 x 21 Blister Packs
Loestrin® 24 Fe	Junel® Fe 24 (norethindrone acetate and ethinyl estradiol tablets USP and ferrous fumarate tablets ¹)	00093-5328-62	1 mg/0.02 mg	3 x 28 Blister Packs
Loestrin® Fe	Junel® Fe 1/20 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets ¹)	00555-9026-58	1 mg/20 mcg	6 x 28 Blister Packs
	Junel® Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets ¹)	00555-9028-58	1.5 mg/30 mcg	6 x 28 Blister Packs
LoSeasonique®	Camrese® Lo (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets) [‡]	00093-6148-82	0.1 mg/0.02 mg; 0.01 mg	2 x 91 Tablet Dispensers
Lybrel®	Amethyst™ (Levonorgestrel and Ethinyl Estradiol Tablets, USP)	00480-3472-24	90 mcg/20 mcg	28 Tablet Dispenser

Oral contraceptives are indicated for use by women to prevent pregnancy. Oral contraceptives do not protect against HIV infection (AIDS) and other sexually transmitted diseases.

IMPORTANT SAFETY INFORMATION

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS

Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, oral contraceptives should not be used by women who are over 35 years of age and smoke.

For more information, please visit
BirthControlForMe.com or call **1-888-TEVA-USA (838-2872)**

(Continued on the next page)

Oral Contraceptive Identification Chart

View the full Prescribing Information by clicking on the Teva Generic product name.

Brand	Teva Generic	NDC	Strength(s)	Size
Minastrin® 24 Fe*	Finzala® (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets†)	00093-8210-62	1 mg/20 mcg	3 x 28 Blister Packs
Mircette®*	Kariva® (desogestrel/ethinyl estradiol and ethinyl estradiol tablets, USP)	00555-9050-58	0.15 mg/0.02 mg; 0.01 mg	6 x 28 Blister Packs
ModiCon®*	Nortrel® 0.5/35 (norethindrone and ethinyl estradiol tablets, USP)	00555-9008-67	0.5 mg/0.035 mg	3 x 28 Blister Packs
Nordette®*	Portia® (levonorgestrel and ethinyl estradiol tablets, USP)	00555-9020-58	0.15 mg/0.03 mg	6 x 28 Blister Packs
Nor-QD®*	Nora-BE® (Norethindrone Tablets USP)‡	00480-3475-16	0.35 mg	6 x 28 Blister Packs
Ortho Cyclen®*	Sprintec® (norgestimate and ethinyl estradiol tablets, USP)	00555-9016-58	0.25 mg/0.035 mg	6 x 28 Blister Packs
Ortho Tri-Cyclen®*	Tri-Sprintec® (norgestimate and ethinyl estradiol tablets, USP)	00555-9018-58	0.18 mg/0.035 mg; 0.215 mg/0.035 mg; 0.25 mg/0.035 mg	6 x 28 Blister Packs
Ortho Tri-Cyclen®* Lo	Tri-Lo-Sprintec® (norgestimate and ethinyl estradiol tablets, USP - triphasic regimen)	00093-2140-62	0.18 mg/0.025 mg; 0.215 mg/0.025 mg; 0.25 mg/0.025 mg	3 x 28 Blister Packs
Ortho-Cept®*	Apri® (desogestrel and ethinyl estradiol tablets, USP)	00555-9043-58	0.15 mg/0.03 mg	6 x 28 Blister Packs
	Reclipsen® (desogestrel and ethinyl estradiol tablets USP)	00093-3304-16	0.15 mg/0.03 mg	6 x 28 Blister Packs
Ortho-Novum®* 1/35	Nortrel® 1/35 (norethindrone and ethinyl estradiol tablets, USP) (21 day regimen)	00555-9009-42	1 mg/0.035 mg	3 x 21 Blister Packs
	Nortrel® 1/35 (norethindrone and ethinyl estradiol tablets, USP) (28 day regimen)	00555-9010-58	1 mg/0.035 mg	6 x 28 Blister Packs
Ortho-Novum®* 7/7/7	Nortrel® 7/7/7 (norethindrone and ethinyl estradiol tablets, USP - triphasic regimen)	00555-9012-58	0.5 mg/0.035 mg; 0.75 mg/0.035 mg; 1 mg/0.035 mg	6 x 28 Blister Packs
Ovcon®* 35	Balziva® (norethindrone and ethinyl estradiol tablets, USP)	00555-9034-58	0.4 mg/0.035 mg	6 x 28 Blister Packs

IMPORTANT SAFETY INFORMATION (continued)

Do not prescribe oral contraceptives to women who are known to have the following conditions:

- A high risk of arterial or venous thrombotic diseases. Examples include women who are known to smoke, if over age 35, or women who have: deep vein thrombosis or pulmonary embolism, now or in the past; cerebrovascular disease; coronary artery disease; thrombotic valvular or thrombotic rhythm diseases of the heart; inherited or acquired hypercoagulopathies; uncontrolled hypertension; diabetes with vascular disease; or headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35.
- Liver tumors, benign or malignant, or liver disease.
- Renal impairment or adrenal insufficiency.
- Undiagnosed abnormal uterine bleeding.
- Pregnancy, because there is no reason to use oral contraceptives during pregnancy.
- Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past.
- Hypersensitivity to any component of the oral contraceptive product.
- Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations.

(Continued on the next page)

For more information, please visit
BirthControlForMe.com or call **1-888-TEVA-USA (838-2872)**



Oral Contraceptive Identification Chart

View the full Prescribing Information by clicking on the Teva Generic product name.

Brand	Teva Generic	NDC	Strength(s)	Size
Quartette®	Rivelsa® (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets†	00093-6031-82	0.15 mg/0.02 mg; 0.15 mg/0.025 mg; 0.15 mg/0.03 mg; 0.01 mg	2 x 91 Tablet Dispensers
Seasonale®*	Jolessa® (levonorgestrel/ethinyl estradiol tablets)†	00555-9123-66	0.15 mg/0.03 mg	3 x 91 Tablet Dispensers
Seasonique®	Camrese® (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets)†	00093-3134-82	0.15 mg/0.03 mg; 0.01 mg	2 x 91 Tablet Dispensers
Tri-Norinyl®*	Aranelle® (norethindrone and ethinyl estradiol tablets, USP)	00555-9066-67	0.5 mg/0.035 mg; 1 mg/0.035 mg	3 x 28 Blister Packs
Triphasil®*	Enpresse® (levonorgestrel and ethinyl estradiol tablets, USP - triphasic regimen)	00555-9047-58	0.05 mg/0.03 mg; 0.075 mg/0.04 mg; 0.125 mg/0.03 mg	6 x 28 Blister Packs
Yasmin®	Ocella® (drospirenone and ethinyl estradiol tablets)†	00555-9131-67	3 mg/0.03 mg	3 x 28 Blister Packs
Yaz®	Vestura® (drospirenone and ethinyl estradiol) tablets, USP	00480-4000-62	3 mg/0.02 mg	3 x 28 Blister Packs

IMPORTANT SAFETY INFORMATION (continued)

Serious adverse reactions associated with the use of oral contraceptives include thrombophlebitis; arterial thromboembolism; pulmonary embolism; myocardial infarction; cerebral hemorrhage; cerebral thrombosis; hypertension; gallbladder disease; hepatic adenomas or benign liver tumors; liver enzyme elevations with concomitant hepatitis C treatment; hyperkalemia; carbohydrate and lipid metabolic effects; ectopic pregnancy; delayed follicular atresia/ovarian cysts; carcinoma of the breast and reproductive organs; genital bleeding irregularities; and onset of or change in migraine/headache.

Common adverse reactions reported for oral contraceptives include menstrual irregularities or disorders; irregular uterine bleeding; nausea; vomiting; breast pain, tenderness or discomfort; headache; migraine; vaginal infection; genital discharge; weight changes (increased or decreased); abdominal pain, tenderness or discomfort; anxiety symptoms; depression or mood changes or disorders; acne; fatigue; irritability; decreased libido; affect lability; flatulence, nervousness, and rash.

Before prescribing any oral contraceptive on this chart, please read the the full Prescribing Information for the specific product by clicking on the Teva Generic product name in the chart.

*Discontinued
†Ferrous fumarate tablets are not USP for dissolution and assay. Strength of ferrous fumarate not denoted in chart.
‡Denotes Authorized Generic product.
The registered marks referenced herein are the property of their respective owners, some of which may no longer be available.
© 2025 Teva Pharmaceuticals USA, Inc. TG-43952 July 2025

